Agreed. Also, only a company which has belief in its drugs would put so much into it as today’s Ann shows by appointing a head of manufacturing and engaging 2 world leading manufacturing companies. Please don’t underestimate how much public and media attention is on Relyvrio’s withdrawal and the void created again for ALS patients. I think the company is striking while the iron is hot and thru a structured and controlled approach because FDA isn’t going to approve anything in a hurry in the near term as it will be a big embarrassment. So moving ahead with speed to capitalise on the tailwinds but in a systematic and scientific manner is the right thing to do. AIMO.
Ann: PharmAust makes Head of Manufacturing appointment, page-8
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
-0.005(2.38%) |
Mkt cap ! $81.16M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 21.0¢ | 20.5¢ | $87.97K | 426.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10300 | 20.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 261000 | 3 |
View Market Depth
| Last trade - 15.59pm 26/06/2024 (20 minute delay) ? |
| PAA (ASX) Chart |